Skip to main content

Table 3 Median overall survival (OS) of pancreatic cancer patients after each treatment

From: Comparison of different Pancreatic cancer treatments: a three-year retrospective study in the oncology center of Tangier university hospital, Morocco

Types of treatment

Folfirinox

Gemcitabine

Gemcitabine-Folfirinox

p-value

Median OS (months ± SD)

6.03 ± 2.02

3.03 ± 1.01

19.70 ± 0.22

< 0.016*

  1. SD: Standard deviation
  2. *The p-value was smaller than 0.016 for the three types of treatment
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us